Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer

被引：1
|
作者：
Bolla, M. [1 ]
Fourneret, P. [1 ]
Descotes, J. -L. [2 ]
机构：
[1] CHU, Clin Univ Cancerol Radiotherapie, F-63011 Grenoble, France
[2] CHU, Clin Univ Urol, F-63011 Grenoble, France
来源：
BULLETIN DU CANCER | 2008年 / 95卷 / 12期
关键词：
high-risk prostate cancer; combination of external irradiation and androgen suppression;
D O I：
10.1684/bdc.2008.0755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment of high-risk prostate cancer-localized or locally advanced-is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.
引用
收藏
页码：1213 / 1218
页数：6
相关论文
共 50 条
  • [21] WHOLE PELVIS RADIOTHERAPY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER
    Spagnoletti, Girolamo
    Marchese, Rita
    Leo, Anna Maria
    Nardella, Grazia
    Piserchia, Maria
    Rignanese, Raffaella
    Bove, Giuseppe
    ANTICANCER RESEARCH, 2012, 32 (05) : 1925 - 1925
  • [22] Radical Radiotherapy for High-Risk Prostate Cancer in Older Men
    Payne, Heather A.
    Hughes, Simon
    ONCOLOGIST, 2012, 17 : 9 - 15
  • [23] Radiotherapy and hormone therapy in patients with high-risk prostate cancer
    Nature Clinical Practice Oncology, 2008, 5 (1): : 8 - 8
  • [24] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    John Thoms
    Jayant S. Goda
    Alexender R. Zlotta
    Neil E. Fleshner
    Theodorus H. van der Kwast
    Stéphane Supiot
    Padraig Warde
    Robert G. Bristow
    Nature Reviews Clinical Oncology, 2011, 8 : 107 - 113
  • [25] Percutaneous prostate cryoablation as treatment for high-risk prostate cancer
    El Hayek, Omar Reda
    Alter, Wladimir, Jr.
    Reggio, Ernesto
    Pompeo, Antonio Carlos L.
    Arap, Sami
    Srougi, Miguel
    CLINICS, 2007, 62 (02) : 109 - 112
  • [26] Surgical treatment and/or radiotherapy in high risk prostate cancer
    Bicaklioglu, Fatih
    Acar, Cenk
    Sozen, Sinan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 97 - 101
  • [27] The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy
    Chierigo, Francesco
    Flammia, Rocco Simone
    Sorce, Gabriele
    Hoeh, Benedikt
    Hohenhorst, Lukas
    Tian, Zhe
    Saad, Fred
    Graefen, Marcus
    Gallucci, Michele
    Briganti, Alberto
    Montorsi, Francesco
    Chun, Felix K. H.
    Shariat, Shahrokh F.
    Guano, Giovanni
    Mantica, Guglielmo
    Borghesi, Marco
    Suardi, Nazareno
    Terrone, Carlo
    Karakiewicz, Pierre I.
    PROSTATE, 2023, 83 (07): : 695 - 700
  • [28] Neoadjuvant and adjuvant treatment in high-risk prostate cancer
    Bandini, Marco
    Fossati, Nicola
    Gandaglia, Giorgio
    Preisser, Felix
    Dell'Oglio, Paolo
    Zaffuto, Emanuele
    Stabile, Armando
    Gallina, Andrea
    Suardi, Nazareno
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    Briganti, Alberto
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 425 - 438
  • [29] Contemporary treatment of high-risk localized prostate cancer
    Tareen, Basir
    Kimmel, Joseph
    Huang, William C.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1069 - 1076
  • [30] Honing Stratification and Treatment for High-risk Prostate Cancer
    Kamran, Sophia C.
    Efstathiou, Jason A.
    EUROPEAN UROLOGY, 2025, 87 (02) : 225 - 227
12345